Literature DB >> 12712443

Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases.

Qin Yang1, Marianne E Hokland, John L Bryant, Yuquing Zhang, Ulf Nannmark, Simon C Watkins, Ronald H Goldfarb, Ronald B Herberman, Per H Basse.   

Abstract

We have shown previously that i.v. injection of interleukin-2-(IL-2) activated natural killer (A-NK) cells together with IL-2 leads to a substantial localization of the A-NK cells into most, but not all, well-established B16 lung metastases in C57BL/6 mice within 12-24 hr. We demonstrate that the morphology of the lung metastases, (loose or more compact in appearance), and their location in the lungs (on the surface or deep in the lung parenchyma) are closely tied to the infiltration-permissiveness of the metastases as well as their sensitivity to treatment with A-NK cells. Although more than 1100 A-NK cells/mm(2) were found in deep metastases with a "loose" morphology (D-L), only 534, 90 and 89 cells/mm(2) were found in surface-loose (S-L), surface-compact (S-C) and deep-compact (D-C) metastases, respectively. The best infiltrated metastases responded best to the A-NK cell therapy. Thus, metastases of the D-L phenotype became reduced by 65-90% after treatment with 2 x 10(6) A-NK cells and IL-2 (120000 IU Peg-IL-2 every 12 hr for 3 days) compared to similar lesions in animals treated with PEG-IL-2 alone. In contrast, poorly infiltrated metastases, that is lesions of the compact phenotype (D-C and S-C) as well as loose metastases on the lung surface (S-L), did not react significantly to this treatment. We conclude that adoptively transferred A-NK cells are able to eliminate even well-established metastases. The existence of metastases that are resistant to infiltration by the transferred effector cells at time of treatment might reduce the efficacy of cell-based immuno-therapeutic ventures. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712443     DOI: 10.1002/ijc.11119

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  IL-2 mediates NK cell proliferation but not hyperactivity.

Authors:  Richa Sharma; Asmita Das
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

2.  Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT.

Authors:  Karin Edsparr; Frank M Speetjens; Adri Mulder-Stapel; Ronald H Goldfarb; Per H Basse; Bo Lennernäs; Peter J K Kuppen; Per Albertsson
Journal:  J Immunother       Date:  2010-06       Impact factor: 4.456

Review 3.  Antitumor activity of NK cells.

Authors:  Q Yang; S R Goding; M E Hokland; P H Basse
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  The ontogeny and fate of NK cells marked by permanent DNA rearrangements.

Authors:  Kristy Pilbeam; Per Basse; Laurent Brossay; Nikola Vujanovic; Rachel Gerstein; Abbe N Vallejo; Lisa Borghesi
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

5.  Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft.

Authors:  Xinxin Song; Se-Hoon Hong; William T Kwon; Lisa M Bailey; Per Basse; David L Bartlett; Yong Tae Kwon; Yong J Lee
Journal:  Mol Cancer Ther       Date:  2016-04-12       Impact factor: 6.261

6.  PTD-mediated loading of tumor-seeking lymphocytes with prodrug-activating enzymes.

Authors:  Qin Yang; Stine K Larsen; Zhibao Mi; Paul D Robbins; Per H Basse
Journal:  AAPS J       Date:  2008-12-23       Impact factor: 4.009

Review 7.  NK cells in the tumor microenvironment.

Authors:  Stine K Larsen; Yanhua Gao; Per H Basse
Journal:  Crit Rev Oncog       Date:  2014

8.  Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.

Authors:  Stephen R Goding; Shaohong Yu; Lisa M Bailey; Michael T Lotze; Per H Basse
Journal:  Clin Immunol       Date:  2016-07-01       Impact factor: 3.969

9.  Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation.

Authors:  Karin Edsparr; Per H Basse; Ronald H Goldfarb; Per Albertsson
Journal:  Cancer Microenviron       Date:  2010-11-27

10.  Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.

Authors:  Chi-Ping Huang; Chun-Chie Wu; Chih-Rong Shyr
Journal:  Cancer Immunol Immunother       Date:  2020-11-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.